- Stockwatch: 2015 - Year of the Grinch?
- Stalled TPP gives generics more time to push back
- With $36bn from Teva, what should Allergan buy next?
- US Capitol Capsule: Record approvals, new legislation: Big things happening in rare diseases
COMMENT Other Informa Comment
- Profile: Janssen R&D boss on the next big thing in medicine & 'ice bucket' funding
- Executive profile: Genzyme's CEO on dark times, transition and the long view